引用次数
引用: 6,025
H-指数: 34
I10-指数 : 72
出版物: 261
Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms
Anna B. Halpern , Nicholas P Howard , Megan Othus , Paul C. Hendrie
Blood 134 1317 -1317
2019
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Ryan C. Lynch , Victor A. Chow , David G. Maloney , Cameron J. Turtle
Blood 134 413 -413
1
2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Ryan C. Lynch , Victor A. Chow , David G. Maloney , Cameron J. Turtle
Blood 134 2889 -2889
2019
A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Ryan D. Cassaday , Oliver W. Press , John M. Pagel , Joseph G. Rajendran
Blood 122 ( 21) 3333 -3333
1
2013
Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant
Colin Phipps , Ajay K. Gopal , Barry E. Storer , Ryan D. Cassaday
Blood 122 ( 21) 3365 -3365
2013
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies
Manuela Matesan , Darrell R. Fisher , Roger Wong , Ajay K. Gopal
The Journal of Nuclear Medicine 61 ( 9) 1300 -1306
1
2020
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial
Ryan D. Cassaday , Lorinda A. Soma , Olga Sala-Torra , Philip A. Stevenson
Blood 132 1419 -1419
1
2018
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy
Victor A. Chow , Ajay K. Gopal , David G. Maloney , Cameron J. Turtle
Blood 132 94 -94
7
2018
Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
Hagop M. Kantarjian , Wendy Stock , Ryan D. Cassaday , Daniel J. DeAngelo
Blood 132 2699 -2699
3
2018
Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Alexandre V. Hirayama , Jordan Gauthier , Kevin A. Hay , Jenna M. Voutsinas
Blood 132 1681 -1681
1
2018
Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study
Solomon A. Graf , Ryan D. Cassaday , Karolyn K. Morris , Heather A. Rasmussen
Blood 132 2954 -2954
2018
Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier , Alexandre V. Hirayama , Kevin A. Hay , Daniel Li
Blood 132 299 -299
32
2018
Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma
Jordan Gauthier , Alexandre V. Hirayama , Kevin A. Hay , Alyssa Sheih
Blood 132 1415 -1415
5
2018
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Sherilyn A. Tuazon , Ryan D. Cassaday , Theodore A. Gooley , Brenda M. Sandmaier
Biology of Blood and Marrow Transplantation 27 ( 1)
6
2021
Cell-specific transgene expression from a widely transcribed promoter using Cre/lox in mice.
Paul J. Grippo , Patrick S. Nowlin , Ryan D. Cassaday , Eric P. Sandgren
Genesis 32 ( 4) 277 -286
25
2002
Allogeneic hematopoietic cell transplantation in mantle cell lymphoma
Ryan D. Cassaday , Ajay K. Gopal
Best Practice & Research Clinical Haematology 25 ( 2) 165 -174
5
2012
Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.
Ryan D. Cassaday , Oliver W. Press , John M. Pagel , Joseph G. Rajendran
Clinical Cancer Research 25 ( 23) 6932 -6938
7
2019
L-carnitine for pegylated-l-asparaginase induced hepatotoxicity.
Matthew Joseph Wieduwilt , Aaron Goodman , Brian Andrew Jonas , Ryan Daniel Cassaday
Journal of Clinical Oncology 35
2
2017
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Wendy Stock , Giovanni Martinelli , Matthias Stelljes , Daniel J. DeAngelo
Journal of Clinical Oncology 36 7030 -7030
5
2018
Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.
Ryan Daniel Cassaday , Daniel J. DeAngelo , Giovanni Martinelli , Wendy Stock
Journal of Clinical Oncology 36 7029 -7029
1
2018